Triptonide acts as a novel antiprostate cancer agent mainly through inhibition of mTOR signaling pathway

Fulu Dong1,2, Ping Yang3, Rui Wang1,2

  • 1Laboratory of Nuclear Receptors and Cancer Research, Basic Medical Research Center, School of Medicine, Nantong University, Nantong, Jiangsu, China.

The Prostate
|June 19, 2019
PubMed
Abstract

Insights

Triptonide effectively inhibits prostate cancer (PCa) cell growth in vitro and in vivo. This study reveals triptonide suppresses PCa by inhibiting mTOR signaling pathways, offering a potential new therapeutic strategy.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Prostate cancer (PCa) incidence is rising, necessitating novel therapeutic agents.
  • Triptonide, identified from Chinese herbal medicine, shows potent anti-cancer activity.
  • This research investigates triptonide's efficacy and mechanisms against PCa.

Purpose of the Study:

  • To evaluate the anti-prostate cancer effects of triptonide in vitro and in vivo.
  • To elucidate the molecular mechanisms underlying triptonide's anti-PCa activity.
  • To explore triptonide as a potential therapeutic candidate for prostate cancer.

Main Methods:

  • Human PCa cell lines (PC3, DU145, LNCap) and normal prostate cells (RWPE) were treated with varying triptonide concentrations.
  • Cell viability, cell cycle, and apoptosis were assessed using cell counting kit-8 and flow cytometry.
  • In vivo efficacy was evaluated in nude mice bearing PCa xenografts, followed by RNA-sequencing (RNA-seq) for mechanism elucidation.

Main Results:

  • Triptonide demonstrated significant inhibition of PCa cell proliferation in vitro (IC50 values 10.259–12.012 nM).
  • Triptonide potently inhibited PCa xenograft growth in vivo (>97.95% inhibition rate).
  • Triptonide induced G2/M cell cycle arrest, promoted apoptosis, and downregulated mTOR phosphorylation and downstream signaling.

Conclusions:

  • Triptonide exhibits significant anti-prostate cancer activity both in vitro and in vivo.
  • The mechanism involves the inhibition of mechanistic target of rapamycin (mTOR) phosphorylation and related signaling pathways.
  • Triptonide represents a promising therapeutic agent for prostate cancer treatment.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.7K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
2.7K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
6.5K